Ken Griffin Catalent, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$56.16 - $60.96 $303,264 - $329,184	-5,400 Reduced 22.22%	18,900 $1.14 Million
Q2 2024 Aug 14, 2024	SELL	$53.58 - $57.02 $2.59 Million - $2.76 Million	-48,400 Reduced 66.57%	24,300 $1.37 Million
Q1 2024 May 15, 2024	SELL	$42.56 - $59.82 $1.49 Million - $2.09 Million	-34,900 Reduced 32.43%	72,700 $4.1 Million
Q4 2023 Feb 14, 2024	SELL	$32.18 - $46.57 $3.2 Million - $4.63 Million	-99,400 Reduced 48.02%	107,600 $4.83 Million
Q3 2023 Nov 14, 2023	SELL	$44.2 - $50.2 $910,520 - $1.03 Million	-20,600 Reduced 9.05%	207,000 $9.42 Million
Q2 2023 Aug 14, 2023	BUY	$31.86 - $67.26 $3.68 Million - $7.77 Million	115,500 Added 103.03%	227,600 $9.87 Million
Q1 2023 May 15, 2023	BUY	$45.44 - $74.26 $4.53 Million - $7.4 Million	99,600 Added 796.8%	112,100 $7.37 Million
Q4 2022 Feb 14, 2023	SELL	$41.39 - $81.0 $8.74 Million - $17.1 Million	-211,100 Reduced 94.41%	12,500 $562,000
Q3 2022 Nov 14, 2022	SELL	$72.36 - $113.1 $2.51 Million - $3.92 Million	-34,700 Reduced 13.43%	223,600 $16.2 Million

513

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.6B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.